March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Comparison Intravitreal Ranibizumab With Photodynamic Therapy And Intravitreal Ranibizumab Monotherapy For Polypoidal Choroidal Vasculopathy
Author Affiliations & Notes
  • Hiroyuki Kagokawa
    Ophthalmology, Asahikawa Medical University, Asahikawa, Japan
  • Akira Takamiya
    Ophthalmology, Asahikawa Medical University, Asahikawa, Japan
  • Eiichi Sato
    Ophthalmology, Asahikawa Medical University, Asahikawa, Japan
  • Daiki Kameyama
    Ophthalmology, Asahikawa Medical University, Asahikawa, Japan
  • Akitoshi Yoshida
    Ophthalmology, Asahikawa Medical University, Asahikawa, Japan
  • Footnotes
    Commercial Relationships  Hiroyuki Kagokawa, None; Akira Takamiya, None; Eiichi Sato, None; Daiki Kameyama, None; Akitoshi Yoshida, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 2063. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Hiroyuki Kagokawa, Akira Takamiya, Eiichi Sato, Daiki Kameyama, Akitoshi Yoshida; Comparison Intravitreal Ranibizumab With Photodynamic Therapy And Intravitreal Ranibizumab Monotherapy For Polypoidal Choroidal Vasculopathy. Invest. Ophthalmol. Vis. Sci. 2012;53(14):2063.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the efficacy of intravitreal ranibizumab (IVR) with photodynamic therapy (PDT) and IVR monotherapy for polypoidal choroidal vasculopathy (PCV).

Methods: : This study retrospectively assessed 32 eyes of 32 patients with visual acuity (VA) between 0.1 and 0.5 due to PCV treated with IVR with PDT or IVR alone and followed for 12 months. The patients were divided into two groups: treatment with one IVR injection with PDT (IVR-PDT group) (16 eyes), and treatment with three consecutive monthly IVR injections alone (IVR group) (16 eyes). Patients were retreated as needed according to retreatment criteria mainly based on VA and optical coherence tomography (OCT) findings every 3 months in the IVR-PDT group and every month in the IVR group. The main outcome measures were the best-corrected VA (BCVA), OCT findings, the presence of polypoidal lesions on indocyanine green angiography (ICGA), and the number of treatments.

Results: : The mean baseline and 3- and 6- and 12-month logMAR VA values were 0.63, 0.47, 0.44, and 0.40, respectively, in the IVR-PDT group and 0.61, 0.37, 0.32, and 0.37 in the IVR group. The mean BCVA in both groups 3, 6 and 12 months after treatment significantly improved (p<0.05) compared to baseline. The subretinal fluid resolved in 12 eyes (92%) in the IVR-PDT group and 10 eyes (77%) in the IVR group. Persistent polypoidal lesions on ICGA were present in one eye (13%) in the IVR-PDT group and six eyes (56%) in the IVR group 3 months after treatment. The number of treatment was 1.4 in the IVR-PDT group and 4.1 in the IVR group for 12 months.

Conclusions: : In eyes with PCV, treatment with IVR-PDT and IVR alone can improve VA for 12 months. Further studies are needed to evaluate functional results for longer periods.

Keywords: clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • age-related macular degeneration • photodynamic therapy 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×